Introduction: The human papillomavirus (HPV) belongs to the papillomaviridae family and is capable of infecting cells in the epithelial tissue and mucous membranes of human beings. Its transmission is based on direct contact with infected skin/mucosa or through sexual contact, which makes it the most common sexually transmitted infection in the world. The course of the infection is transient, that is, in most cases it regresses spontaneously, but due to the integration of the viral genome into the cell, it can end up evolving. There are currently more than 450 types of HPV, divided into high-risk and low-risk HPVs. When the infection is caused by a high-risk HPV, it is more likely to be persistent and, if this occurs, there is the possibility of cancer precursor lesions appearing; in cases where these lesions are not properly identified and treated, the appearance of a neoplasm in the infected area is imminent. HPV is associated with various types of cancer, but is mainly associated with cervical cancer (CCU). Objectives: To identify the predominance of oncological staging of CCU associated with HPV infection in patients treated at the Ophir Loyola Hospital (HOL) between 2008-2012. Methods: This work is based on a descriptive and retrospective study of the oncological staging of patients associated with HPV infection diagnosed and treated at the HOL during the stipulated period. Firstly, the samples were separated, obtained from retrospective studies carried out by the Papillomavirus and Retrovirus Laboratory, located at the Evandro Chagas Institute-Pará. The samples were prepared for RT-PCR methodology to identify the type of viral infection. The resulting data was analyzed to identify the average age, the most frequent staging and the type of HPV most present in the cases. The study was approved by the ethics committee, CAAE: 51144515.0.0000.0019. Results: A total of 438 patients seen at the HOL during the period were analyzed, with a mean age of 53,6 years, which according to the WHO is middle-aged. As for the staging, three were found to be more prevalent than the others: Invasive Carcinoma (26.48%, 116/438); Epidermoid Carcinoma (20.09%, 88/438) and Adenocarcinoma (14.84%, 65/438). It was also possible to identify a higher prevalence of HPV type 16 infection (18.26%, 80/438), followed by HPV 18 infection (2.74%, 12/438). Conclusion: After analyzing, we can conclude that, during the stipulated period, there was a predominance of advanced cases of oncological staging of CCU associated with HPV infection, with those presented already corresponding to established cancer. In addition, it was possible to identify a marked predominance of HPV 16 in the group studied, which is one of the main types associated with the oncogenic capacity of the virus. The result obtained is in line with the literature and epidemiological studies, since these studies point to HPV 16, on a global scale, as an agent highly associated with cases of precursor lesions and episodes of CCU itself. It was also possible to identify a higher average age of these patients, which corroborates the appearance of more severe cases of the infection.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
